Back to top
more

Novogen Limited (KZIA)

(Delayed Data from NSDQ)

$0.29 USD

0.29
304,764

-0.02 (-5.47%)

Updated Apr 16, 2024 03:52 PM ET

After-Market: $0.30 +0.01 (3.38%) 4:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for KZIA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Novogen Limited [KZIA]

Reports for Purchase

Showing records 1 - 20 ( 46 total )

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 1

04/11/2023

Company Report

Pages: 8

Key Clinical Readouts Expected in 2023; Upgrade to Buy with $2.00 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: LEE S

Price: 12.50

Research Provided by a Third Party

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 2

02/01/2023

Company Report

Pages: 2

Reinvestment period with increased R&D focus

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 3

12/19/2022

Company Report

Pages: 2

Collaboration may expand utility to combo therapies

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 4

12/07/2022

Company Report

Pages: 6

EVT801 data published in peer-reviewed journal

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 12.50

Research Provided by a Third Party

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 5

12/07/2022

Company Report

Pages: 6

EVT801 data published in peer-reviewed journal

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 12.50

Research Provided by a Third Party

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 6

11/01/2022

Company Report

Pages: 2

Q123 cash flows in line with our estimates

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 7

10/10/2022

Company Report

Pages: 2

PNOC022 trial expanded

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 8

09/06/2022

Company Report

Pages: 3

Doubling down on clinical development

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 9

08/08/2022

Company Report

Pages: 9

Ambiguity in GBM but pipeline still busy

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 12.50

Research Provided by a Third Party

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 10

08/02/2022

Company Report

Pages: 6

Phase 3 GBM Study Misses Interim Milestone; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: LEE S

Price: 12.50

Research Provided by a Third Party

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 11

07/07/2022

Company Report

Pages: 3

Paxalisib awarded RPDD in AT/RT

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 12

06/21/2022

Company Report

Pages: 2

Paxalisib receives ODD for AT/RT

Provider: Edison Investment Research Limited

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 13

05/24/2022

Company Report

Pages: 8

Deep dive into childhood brain cancer

Provider: Edison Investment Research Limited

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 14

03/28/2022

Company Report

Pages: 8

Several upcoming catalysts

Provider: Edison Investment Research Limited

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 15

12/07/2021

Daily Note

Pages: 3

Phase 2 In Line With Expectations; A Catalyst-Rich 2022; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LEE S

Price: 5.00

Research Provided by a Third Party

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 16

10/14/2021

Company Report

Pages: 7

Multiple paxalisib data points expected in Q4

Provider: Edison Investment Research Limited

Analyst: JACOBS M

Price: 12.50

Research Provided by a Third Party

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 17

10/13/2021

Company Report

Pages: 7

Multiple paxalisib data points expected in Q4

Provider: Edison Investment Research Limited

Analyst: JACOBS M

Price: 12.50

Research Provided by a Third Party

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 18

04/20/2021

Daily Note

Pages: 4

Expanding Pipeline With EVT801 In-License; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LEE S

Price: 10.00

Research Provided by a Third Party

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 19

04/20/2021

Company Report

Pages: 6

New asset to target tumor lymphangiogenesis

Provider: Edison Investment Research Limited

Analyst: CALLOWAY N

Price: .00

Research Provided by a Third Party

Company: Novogen Limited

Industry: Medical - Biomedical and Genetics

Record: 20

04/19/2021

Company Report

Pages: 6

New asset to target tumor lymphangiogenesis

Provider: Edison Investment Research Limited

Analyst: CALLOWAY N

Price: .00

Research Provided by a Third Party